4.7 Article

Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 25, Issue 1, Pages 84-90

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1016/S0893-133X(00)00230-X

Keywords

Alzheimer's disease; melanotransferrin; biochemical marker

Ask authors/readers for more resources

The protein melanotransferrin (p97) is associated with the brain lesions of Alzheimer's disease (AD) and is a potential marker of the disorder. We measured serum p97 concentrations in 211 subjects: 71 patients with AD, 56 patients with non-AD-type dementia, and 84 normal control subjects. Serum p97 concentrations were elevated 3- to 4-fold in AD (median 15.00 pg/mul, interquartile range 10.20-17.00 pg/mul) as compared to non AD dementia (2.85 pg/mul, 1.93-7.15 pg/mul) and normal controls (3.20 pg/mul, 2.55-3.95 pg/mul). The mean elevation tons significant at 13.54 +/- 3.72 pg/mul, even in the 38 subjects with mild AD (CDR stage 0.5-1). Receiver operating characteristic analyses confirmed an optimal diagnostic threshold of 10.0 pg/mul, which yielded over-all accuracy of 0.882 to 0.915. Serum p97 is a candidate marker of AD, even in the early stage when clinical diagnosis is most uncertain. [Neuropsychopharmacology 25:84-90, 2001] (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available